2017
DOI: 10.1016/s0016-5085(17)30804-1
|View full text |Cite
|
Sign up to set email alerts
|

A Novel Derivative of Eicosapentaenoic Acid Reduces Intestinal Tumor Burden in the APCÎ"14/+ Mouse Model of Familial Adenomatous Polyposis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2017
2017
2017
2017

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…TP-252 EPA-FFA is a new n-3 PUFAs enteric-coated powder preparation, in which two molecules of EPA in FFA form are bound to a scaffold made from mineral amino-acid. This preparation easily dissociates in aqueous media, displaying a favourable safety profile [ 103 ]. Maki et al [ 104 ] reported on the superiority of MAT9001, a new n-3 PUFAs engineered-matrix, delayed-release 1 g capsule formulation to deliver EPA and DHA, versus ethyl-ester EPA in dyslipidaemia.…”
Section: Introductionmentioning
confidence: 99%
“…TP-252 EPA-FFA is a new n-3 PUFAs enteric-coated powder preparation, in which two molecules of EPA in FFA form are bound to a scaffold made from mineral amino-acid. This preparation easily dissociates in aqueous media, displaying a favourable safety profile [ 103 ]. Maki et al [ 104 ] reported on the superiority of MAT9001, a new n-3 PUFAs engineered-matrix, delayed-release 1 g capsule formulation to deliver EPA and DHA, versus ethyl-ester EPA in dyslipidaemia.…”
Section: Introductionmentioning
confidence: 99%